. | Intervention . | Control . | P value (all patients) . | ||||||
---|---|---|---|---|---|---|---|---|---|
All patients (n = 1,220) . | A1C ≥8% (64 mmol/mol) (n = 569) . | LDL cholesterol ≥100 mg/dL (n = 348) . | SBP >140/90 mmHg (n = 388) . | All patients (n = 1,158) . | A1C ≥8% 64 mmol/mol (n = 533) . | LDL cholesterol ≥100 mg/dL (n = 315) . | SBP ≥140/90 mmHg (n = 403) . | ||
Site, n (%) | |||||||||
Site A | 161 (13.2) | 52 (9.1) | 31 (8.9) | 91 (23.5) | 136 (11.7) | 46 (8.6) | 25 (7.9) | 73 (18.1) | 0.576 |
Site B | 834 (68.4) | 421 (74.0) | 269 (77.3) | 203 (52.3) | 806 (69.6) | 400 (75.0) | 246 (78.1) | 228 (56.6) | |
Site C | 152 (12.5) | 57 (10.0) | 38 (10.9) | 67 (17.3) | 137 (11.8) | 49 (9.2) | 31 (9.8) | 67 (16.6) | |
Site D | 73 (6.0) | 39 (6.9) | 10 (2.9) | 27 (7.0) | 79 (6.8) | 38 (7.1) | 13 (4.1) | 35 (8.7) | |
Female sex, n (%) | 623 (51.1) | 274 (48.2) | 189 (54.3) | 203 (52.3) | 615 (53.1) | 263 (49.3) | 184 (58.4) | 216 (53.6) | 0.319 |
Race, n (%) | |||||||||
Asian | 171 (14.0) | 88 (15.5) | 62 (17.8) | 35 (9.0) | 183 (15.8) | 89 (16.7) | 56 (17.8) | 48 (11.9) | 0.422 |
Black | 150 (12.3) | 64 (11.2) | 50 (14.4) | 47 (12.1) | 140 (12.1) | 66 (12.4) | 44 (14.0) | 51 (12.7) | |
Other/unknown | 85 (7.0) | 46 (8.1) | 25 (7.2) | 25 (6.4) | 66 (5.7) | 33 (6.2) | 18 (5.7) | 21 (5.2) | |
White | 814 (66.7) | 371 (65.2) | 211 (60.6) | 281 (72.4) | 769 (66.4) | 345 (64.7) | 197 (62.5) | 283 (70.2) | |
Hispanic | |||||||||
No | 358 (29.3) | 134 (23.6) | 77 (22.1) | 171 (44.1) | 329 (28.4) | 125 (23.5) | 61 (19.4) | 165 (40.9) | 0.825 |
Unknown | 717 (58.8) | 356 (62.6) | 231 (66.4) | 183 (47.2) | 695 (60.0) | 333 (62.5) | 213 (67.6) | 208 (51.6) | |
Yes | 145 (11.9) | 79 (13.9) | 40 (11.5) | 34 (8.8) | 134 (11.6) | 75 (14.1) | 41 (13.0) | 30 (7.4) | |
Age at new prescription (years), n (%) | |||||||||
18–39 | 59 (4.8) | 36 (6.3) | 19 (5.5) | 6 (1.5) | 59 (5.1) | 34 (6.4) | 18 (5.7) | 15 (3.7) | 0.553 |
40–64 | 653 (53.5) | 341 (59.9) | 199 (57.2) | 171 (44.1) | 594 (51.3) | 316 (59.3) | 179 (56.8) | 159 (39.5) | |
≥65 | 508 (41.6) | 192 (33.7) | 130 (37.4) | 211 (54.4) | 505 (43.6) | 183 (34.3) | 118 (37.5) | 229 (56.8) | |
Age at new prescription (years)* | |||||||||
Mean ± SD | 61.67 ± 13.03 | 59.10 ± 12.43 | 59.70 ± 12.63 | 66.47 ± 12.49 | 62.04 ± 13.37 | 59.24 ± 12.79 | 59.93 ± 13.41 | 66.23 ± 13.22 | 0.390 |
Median (minimum–maximum) | 62 (19–94) | 60 (19–94) | 60.00 (22–91) | 66 (33–94) | 63 (19–96) | 60 (19–96) | 60 (24–92) | 67 (28–92) | |
Drug coverage at new prescription, n (%)* | 1,020 (83.6) | 485 (85.2) | 302 (86.8) | 298 (76.8) | 975 (84.2) | 459 (86.1) | 271 (86.0) | 322 (79.9) | 0.695 |
Baseline value | |||||||||
Mean ± SD | 9.76 ± 1.66% (83 mmol/mol) | 135.1 ± 31.09 | 155.2 ± 13.51 | 9.83 ± 1.65% (84 mmol/mol) | 138.0 ± 30.56 | 154.6 ± 13.78 | |||
Median (minimum–maximum) | 9.3% (8.0–17.9%) (78 mmol/mol) | 126.5 mg/dL (100.0–281.0 mg/dL) | 152.0 mmHg (140.0–214.0 mmHg) | 9.4% (8.0–15.7%) (79 mmol/mol) | 130.0 mg/dL(100.0–274.0 mg/dL) | 150.0 mmHg (140.0 –220.0 mmHg) |
. | Intervention . | Control . | P value (all patients) . | ||||||
---|---|---|---|---|---|---|---|---|---|
All patients (n = 1,220) . | A1C ≥8% (64 mmol/mol) (n = 569) . | LDL cholesterol ≥100 mg/dL (n = 348) . | SBP >140/90 mmHg (n = 388) . | All patients (n = 1,158) . | A1C ≥8% 64 mmol/mol (n = 533) . | LDL cholesterol ≥100 mg/dL (n = 315) . | SBP ≥140/90 mmHg (n = 403) . | ||
Site, n (%) | |||||||||
Site A | 161 (13.2) | 52 (9.1) | 31 (8.9) | 91 (23.5) | 136 (11.7) | 46 (8.6) | 25 (7.9) | 73 (18.1) | 0.576 |
Site B | 834 (68.4) | 421 (74.0) | 269 (77.3) | 203 (52.3) | 806 (69.6) | 400 (75.0) | 246 (78.1) | 228 (56.6) | |
Site C | 152 (12.5) | 57 (10.0) | 38 (10.9) | 67 (17.3) | 137 (11.8) | 49 (9.2) | 31 (9.8) | 67 (16.6) | |
Site D | 73 (6.0) | 39 (6.9) | 10 (2.9) | 27 (7.0) | 79 (6.8) | 38 (7.1) | 13 (4.1) | 35 (8.7) | |
Female sex, n (%) | 623 (51.1) | 274 (48.2) | 189 (54.3) | 203 (52.3) | 615 (53.1) | 263 (49.3) | 184 (58.4) | 216 (53.6) | 0.319 |
Race, n (%) | |||||||||
Asian | 171 (14.0) | 88 (15.5) | 62 (17.8) | 35 (9.0) | 183 (15.8) | 89 (16.7) | 56 (17.8) | 48 (11.9) | 0.422 |
Black | 150 (12.3) | 64 (11.2) | 50 (14.4) | 47 (12.1) | 140 (12.1) | 66 (12.4) | 44 (14.0) | 51 (12.7) | |
Other/unknown | 85 (7.0) | 46 (8.1) | 25 (7.2) | 25 (6.4) | 66 (5.7) | 33 (6.2) | 18 (5.7) | 21 (5.2) | |
White | 814 (66.7) | 371 (65.2) | 211 (60.6) | 281 (72.4) | 769 (66.4) | 345 (64.7) | 197 (62.5) | 283 (70.2) | |
Hispanic | |||||||||
No | 358 (29.3) | 134 (23.6) | 77 (22.1) | 171 (44.1) | 329 (28.4) | 125 (23.5) | 61 (19.4) | 165 (40.9) | 0.825 |
Unknown | 717 (58.8) | 356 (62.6) | 231 (66.4) | 183 (47.2) | 695 (60.0) | 333 (62.5) | 213 (67.6) | 208 (51.6) | |
Yes | 145 (11.9) | 79 (13.9) | 40 (11.5) | 34 (8.8) | 134 (11.6) | 75 (14.1) | 41 (13.0) | 30 (7.4) | |
Age at new prescription (years), n (%) | |||||||||
18–39 | 59 (4.8) | 36 (6.3) | 19 (5.5) | 6 (1.5) | 59 (5.1) | 34 (6.4) | 18 (5.7) | 15 (3.7) | 0.553 |
40–64 | 653 (53.5) | 341 (59.9) | 199 (57.2) | 171 (44.1) | 594 (51.3) | 316 (59.3) | 179 (56.8) | 159 (39.5) | |
≥65 | 508 (41.6) | 192 (33.7) | 130 (37.4) | 211 (54.4) | 505 (43.6) | 183 (34.3) | 118 (37.5) | 229 (56.8) | |
Age at new prescription (years)* | |||||||||
Mean ± SD | 61.67 ± 13.03 | 59.10 ± 12.43 | 59.70 ± 12.63 | 66.47 ± 12.49 | 62.04 ± 13.37 | 59.24 ± 12.79 | 59.93 ± 13.41 | 66.23 ± 13.22 | 0.390 |
Median (minimum–maximum) | 62 (19–94) | 60 (19–94) | 60.00 (22–91) | 66 (33–94) | 63 (19–96) | 60 (19–96) | 60 (24–92) | 67 (28–92) | |
Drug coverage at new prescription, n (%)* | 1,020 (83.6) | 485 (85.2) | 302 (86.8) | 298 (76.8) | 975 (84.2) | 459 (86.1) | 271 (86.0) | 322 (79.9) | 0.695 |
Baseline value | |||||||||
Mean ± SD | 9.76 ± 1.66% (83 mmol/mol) | 135.1 ± 31.09 | 155.2 ± 13.51 | 9.83 ± 1.65% (84 mmol/mol) | 138.0 ± 30.56 | 154.6 ± 13.78 | |||
Median (minimum–maximum) | 9.3% (8.0–17.9%) (78 mmol/mol) | 126.5 mg/dL (100.0–281.0 mg/dL) | 152.0 mmHg (140.0–214.0 mmHg) | 9.4% (8.0–15.7%) (79 mmol/mol) | 130.0 mg/dL(100.0–274.0 mg/dL) | 150.0 mmHg (140.0 –220.0 mmHg) |
Note that a given patient could have elevations in more than one clinical domain.
*Time of new prescription for first uncontrolled condition when pooled over all conditions.